Urotensin II in Chronic Kidney Diseases and Kidney Transp... | NCT01098799

Studies
Urotensin II in Chronic Kidney Diseases and Kidney Transplants

NCT01098799

Sponsor

Vakif Gureba Training and Research Hospital

Status

Completed

Last Update Posted

Jun 13, 2013Estimated

Enrollment

110Actual

Phase

Not provided

Conditions

Chronic Renal Disease

Interventions

Not provided

Countries

Turkey (Türkiye)

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Jun 2013

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Apr 2010

Primary Completion Date

Jul 2010Actual

Completion Date

Jul 2010Actual

First Submitted Date

Apr 2, 2010

First Submission Date that Met QC Criteria

Apr 2, 2010

First Posted Date

Apr 5, 2010Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Jun 12, 2013

Last Update Posted Date

Jun 13, 2013Estimated

Sponsor/Collaborators Module

Responsible Party, by Official Title

Mehmet Hursitoglu, Chair, Vakif Gureba Training and Research HospitalPrincipal Investigator

Lead Sponsor

Vakif Gureba Training and Research HospitalOTHER

Collaborators

Not provided

Oversight Module

Has Data Monitoring Committee (DMC)

Yes

Is FDA Regulated Drug

Not provided

Is FDA Regulated Device

Not provided

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

The investigators are planning to study the serum level of Urotensin II in chronic kidney disease patients, kidney transplants, and healthy controls.

Detailed Description

The investigators will determine the urotensin II levels in Chronic kidney disease patients, kidney transplants, and healthy controls.

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

No data available

No data is available for this block.

Enrollment

110Actual

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Control		Healthy controls
Chronic kidney disease-1		Chronic kidney disease not taking dialysis treatment
Kidney Transplant		Kidney transplants

Interventions

Not provided

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
serum Urotensin II(UII)level	We tried to compare UII level in normal, chronic kidney disease and kidney transplant patients group	at enrollment

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Age more than 18

Exclusion Criteria:

Inability to give a written consent

Accepts Healthy Volunteers

Yes

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

90 Years

Standard Ages

AdultOlder Adult

Study Population

Healthy controls,CRF patients and kidney transplants aged more than 18

Sampling Method

Non-Probability Sample

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
Tufan Tukek, MD	Vakif Gureba Training & Research Hospital	Study Director

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Vakif Gureba Training & Research Hospital		Istanbul		34100	Turkey (Türkiye)

Condition Browse Module

MeSH Terms

ID	Term
D051436	Renal Insufficiency, Chronic

Ancestor Terms

ID	Term
D051437	Renal Insufficiency
D007674	Kidney Diseases
D014570	Urologic Diseases
D052776	Female Urogenital Diseases

Browse Leaves

Not provided

Browse Branches

Not provided